Advice
Following a full submission
quetiapine (Seroquel) is not recommended for use within NHS Scotland for the treatment of major depressive episodes associated with bipolar disorder.
In monotherapy studies quetiapine was superior to placebo and compared favourably with two active comparators. Efficacy relative to current practice for the management of depression in the framework of bipolar disorder in NHS Scotland involving combination therapy with a mood stabiliser or an atypical antipsychotic plus an antidepressant, was not demonstrated.
The licence holder has indicated their intention to resubmit.
Download detailed advice92KB (PDF)
Medicine details
- Medicine name:
- quetiapine fumerate (Seroquel)
- SMC ID:
- 549/09
- Indication:
- Bipolar disorder
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 October 2009